Ori is supporting the heroes of cell and gene therapy who are rewriting human history.
Jason C. Foster joins tools and services representatives on a panel discussion to explore their different approaches to scaling CGT manufacturing
Today, only a small percentage of patients are able to access lifesaving cell and gene therapies.
These therapies are too hard to manufacture,
Too expensive to make widely available,
And not commercially viable due to high costs, low throughput, and lack of reproducibility.
Together, we are on a mission to change that.
Ori is empowering scientists with flexible tools that streamline development and help to enable widespread patient access to life-saving cell and gene therapies. Historically, scientists have had to compromise biological performance for automation. With IRO®, there is no trade-off. Offering both flexibility and scalability, IRO® supports accelerated development, minimizes batch failures, increases throughput, and reduces costs.
To enable widespread patient access to lifesaving cell and gene therapies, you need both superior biological performance and the benefits of digitally enabled automation to maximize your clinical and commercial impact.
Ori has taken a biology-first approach understanding that cell quality, potency, and yield are critical to successful patient outcomes.
By automating manual steps and deskilling processes, Ori enables high throughput, high quality, and lower-cost manufacturing essential to reach scale and maximize both clinical and commercial impact.
The cloud-native Ori platform helps to accelerate process development, reduce batch failures, and streamline batch release, resulting in shorter development times and more efficient manufacturing.
United in our mission to enable widespread patient access
The latest learnings, opinions, and events
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
March 18, 2025 – Preferred Partner Network (PPN) members will …
Read more
Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs and Commercial CGT Manufacturers
January 7, 2025 – Six months after its unveiling, the …
Read more
Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies
December 10, 2024 – New collaboration showcases successful integration of …
Read more
Let’s enable widespread patient access, together.
Oribiotech Ltd 2025 © All rights reserved.
Oribiotech Ltd is registered in England and Wales. "Ori”, “Ori Biotech”, "Iro" and the O icon are registered trademarks of Oribiotech Ltd.
Company registration 09757696.
Notifications
